ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our statistical analysis of the dynamic (long-term) treatment response of CP-CML patients within the DASISION trial demonstrates differences in the average BCR-ABL dynamics between first-line imatinib and dasatinib treatment.